摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4-dichloro-6-(4-ethoxy-phenyl)-pyrimidine | 881194-50-9

中文名称
——
中文别名
——
英文名称
2,4-dichloro-6-(4-ethoxy-phenyl)-pyrimidine
英文别名
2,4-Dichloro-6-(4-ethoxyphenyl)pyrimidine
2,4-dichloro-6-(4-ethoxy-phenyl)-pyrimidine化学式
CAS
881194-50-9
化学式
C12H10Cl2N2O
mdl
MFCD20848871
分子量
269.13
InChiKey
GONFBGGRSMWHGI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    35
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • Novel pyrimidine compounds, process for their preparation and compositions containing them
    申请人:Pal Manojit
    公开号:US20060084645A1
    公开(公告)日:2006-04-20
    The present invention provides new heterocyclic compounds, particularly substituted pyrimidines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan.
    本发明提供了新的杂环化合物,特别是取代的嘧啶,制备和使用这些杂环化合物的方法和组合物,以及治疗各种疾病和疾病状态的方法,包括动脉粥样硬化、关节炎、再狭窄、糖尿病肾病或血脂异常,或由Perlecan低表达介导的疾病状态。
  • NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
    申请人:Reddy US Therapeutics, Inc.
    公开号:EP1796673A2
    公开(公告)日:2007-06-20
  • US7820654B2
    申请人:——
    公开号:US7820654B2
    公开(公告)日:2010-10-26
  • [EN] NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES DE PYRIMIDINE, LEUR PROCEDE DE PREPARATION, ET COMPOSITIONS LES CONTENANT
    申请人:REDDY US THERAPEUTICS INC
    公开号:WO2006034473A2
    公开(公告)日:2006-03-30
    The present invention provides new heterocyclic compounds, particularly substituted pyrimidines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan.
查看更多